UK pharmaceutical giant GSK says it will pay as much as $2.2bn (£1.68bn) to settle thousands of cases in US courts over claims that a discontinued version of its heartburn drug Zantac caused cancer.
GSK and other drugmakers fending off litigation claiming that gastrointestinal drug Zantac or a generic caused cancer have won a supreme court ruling in Canada, after also chalking up wins in the US.
In September 2019, the FDA announced that a small amount of cancer-causing chemicals, known as N-Nitrosodimethylamine (NDMA), were found in certain heartburn medications, such as Zantac.
UK pharmaceutical giant GSK says it will pay as much as $2.2bn (£1.68bn) to settle thousands of cases in US courts over claims that a discontinued version of its heartburn drug Zantac caused cancer.
Shares in pharmaceutical company GlaxoSmithKline (GSK) surged more than 6% after the company revealed it had reached a settlement of up to $2.2bn (€2.01bn) to end tens of thousands of lawsuits ...
Although GSK has consented to the settlement, the firm has rejected any admission of guilt, citing an absence of "consistent or reliable evidence" connecting Zantac to cancer. Additionally, the ...
GSK earlier this month agreed to pay $2.3 billion to end lawsuits alleging that Zantac caused cancer, despite the group not admitting liability. Stripping out the litigation costs, GSK said ...
Cancer fatalism-the belief that death is inevitable when cancer is present-has been identified as a barrier to participation in cancer screening, detection, and treatment. Yet this literature has ...
Nov. 11, 2024 — A team of scientists has used a novel approach to identify protein degraders that target Pin1, a protein involved in pancreatic cancer ... DNA Packaging Directly Affects How Fast ...
Someone watching over you? This is your lucky day! You’ve got spiritual protection as the moon and Jupiter harmonize. Today’s forecast: zero drama. Why? A guide has your back! A business ...